Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Wilms Tumor | 1 | 2018 | 8 | 0.77 | Why? |
| Ovarian Neoplasms | 1 | 2018 | 465 | 0.49 | Why? |
| Kidney Neoplasms | 1 | 2018 | 832 | 0.40 | Why? |
| State Medicine | 1 | 2018 | 2847 | 0.28 | Why? |
| Organ Dysfunction Scores | 2 | 2020 | 1475 | 0.26 | Why? |
| Risk Assessment | 5 | 2020 | 25439 | 0.22 | Why? |
| Fontan Procedure | 1 | 2019 | 42 | 0.19 | Why? |
| Ulnar Artery | 1 | 2017 | 11 | 0.18 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 256 | 0.18 | Why? |
| INDEL Mutation | 1 | 2018 | 128 | 0.17 | Why? |
| Anal Canal | 1 | 2020 | 367 | 0.17 | Why? |
| Arteriovenous Shunt, Surgical | 1 | 2017 | 93 | 0.16 | Why? |
| Gastrectomy | 1 | 2018 | 225 | 0.16 | Why? |
| Oseltamivir | 1 | 2020 | 583 | 0.16 | Why? |
| Veins | 1 | 2017 | 168 | 0.16 | Why? |
| Radial Artery | 1 | 2017 | 132 | 0.16 | Why? |
| Triglycerides | 1 | 2018 | 478 | 0.15 | Why? |
| Upper Extremity | 1 | 2017 | 193 | 0.14 | Why? |
| Patient Care Planning | 1 | 2020 | 582 | 0.14 | Why? |
| Genetic Association Studies | 1 | 2018 | 559 | 0.14 | Why? |
| Cardiovascular Diseases | 2 | 2020 | 11497 | 0.14 | Why? |
| Analgesics | 1 | 2018 | 451 | 0.13 | Why? |
| Cholesterol | 1 | 2018 | 660 | 0.13 | Why? |
| Coronavirus OC43, Human | 1 | 2021 | 1157 | 0.13 | Why? |
| China | 13 | 2021 | 50654 | 0.12 | Why? |
| Stomach Neoplasms | 1 | 2018 | 477 | 0.12 | Why? |
| Adenosine Monophosphate | 2 | 2020 | 5652 | 0.12 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.12 | Why? |
| Neoplasm Recurrence, Local | 1 | 2018 | 1063 | 0.11 | Why? |
| Decision Support Techniques | 1 | 2018 | 903 | 0.11 | Why? |
| Polymorphism, Genetic | 1 | 2018 | 1074 | 0.10 | Why? |
| Hypertension | 3 | 2021 | 8895 | 0.10 | Why? |
| Pulmonary Disease, Chronic Obstructive | 2 | 2018 | 3832 | 0.10 | Why? |
| Pyrazines | 1 | 2020 | 1783 | 0.10 | Why? |
| Heart Defects, Congenital | 1 | 2019 | 933 | 0.10 | Why? |
| Biomarkers, Tumor | 1 | 2018 | 1314 | 0.10 | Why? |
| Amides | 1 | 2020 | 1864 | 0.10 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.09 | Why? |
| Risk Factors | 8 | 2020 | 71621 | 0.09 | Why? |
| Predictive Value of Tests | 2 | 2020 | 9537 | 0.09 | Why? |
| Coronavirus Infections | 9 | 2020 | 253789 | 0.08 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2021 | 3892 | 0.08 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.08 | Why? |
| Female | 19 | 2021 | 380317 | 0.08 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.08 | Why? |
| Influenza, Human | 2 | 2021 | 10779 | 0.08 | Why? |
| Infusions, Intravenous | 2 | 2020 | 1224 | 0.08 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 5277 | 0.07 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.07 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Male | 18 | 2021 | 367725 | 0.07 | Why? |
| Hospital Mortality | 4 | 2021 | 22087 | 0.07 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.07 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.06 | Why? |
| Humans | 25 | 2021 | 930598 | 0.06 | Why? |
| Treatment Failure | 2 | 2020 | 2106 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.06 | Why? |
| Sepsis | 1 | 2020 | 3517 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.06 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.06 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.06 | Why? |
| Time Factors | 6 | 2020 | 31397 | 0.06 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.05 | Why? |
| Renal Dialysis | 1 | 2017 | 4358 | 0.05 | Why? |
| Equivalence Trials as Topic | 1 | 2020 | 242 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.05 | Why? |
| Quality of Life | 1 | 2021 | 9820 | 0.05 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.05 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.05 | Why? |
| Aged | 12 | 2021 | 215776 | 0.05 | Why? |
| Comorbidity | 5 | 2021 | 34796 | 0.05 | Why? |
| Double-Blind Method | 2 | 2020 | 5988 | 0.05 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2020 | 673 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2020 | 6543 | 0.04 | Why? |
| Vascular Patency | 1 | 2017 | 96 | 0.04 | Why? |
| Muscle Weakness | 1 | 2021 | 406 | 0.04 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2018 | 9659 | 0.04 | Why? |
| Graft Occlusion, Vascular | 1 | 2017 | 105 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Respiratory Syncytial Viruses | 1 | 2020 | 612 | 0.04 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2020 | 782 | 0.04 | Why? |
| Cholesterol, HDL | 1 | 2018 | 439 | 0.04 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.03 | Why? |
| Cholesterol, LDL | 1 | 2018 | 499 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Myalgia | 1 | 2020 | 1015 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.03 | Why? |
| Pharynx | 1 | 2020 | 1544 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.03 | Why? |
| Child | 2 | 2019 | 70012 | 0.03 | Why? |
| Treatment Outcome | 4 | 2020 | 51732 | 0.03 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.03 | Why? |
| Nomograms | 1 | 2018 | 790 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2018 | 1755 | 0.03 | Why? |
| Adult | 7 | 2021 | 244371 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Shock, Septic | 1 | 2020 | 1313 | 0.03 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Fatigue | 1 | 2021 | 2479 | 0.02 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.02 | Why? |
| Sleep Wake Disorders | 1 | 2021 | 1463 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Diabetes Complications | 1 | 2020 | 2358 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.02 | Why? |
| Cause of Death | 1 | 2020 | 4823 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.02 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.02 | Why? |
| Cough | 1 | 2020 | 4891 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2019 | 9893 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Postoperative Complications | 1 | 2019 | 5861 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Infant | 1 | 2019 | 30274 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Child, Preschool | 1 | 2019 | 36283 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.01 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
Fan's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(151)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(272)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_